Article

Interleukin-6 receptor genetic variation and tocilizumab treatment response to COVID-19

2021-04-27

Abstract excerpt

<h4>ABSTRACT</h4> Interleukin-6 receptor (IL6R) stimulates the inflammatory pathways as part of the acute-phase response to infection. Tocilizumab is a monoclonal antibody that inhibits both membrane-bound and soluble IL6R and is used to treat inflammatory conditions, including COVID-19. Despite the disproportionate incidence of COVID-19 among underserved, racial, and ethnic minority populations, the efficacy of t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 89aa6596-9cf1-5f6f-b645-421527688d9b
DOI: 10.1101/2021.04.24.21256047

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Interleukin-6 receptor genetic variation and tocilizumab treatment response to COVID-19DOI 10.1101/2021.04.24.21256047Read

Differential Associations of Interleukin 6 Receptor Variant Across Genetic Ancestries and Implications for Targeted TherapiesSemantic proximity Read

Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19.Semantic proximity Read

Genetically downregulated interleukin-6 signaling is associated with a favorable cardiometabolic profile: a phenome-wide association studySemantic proximity Read

Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19Semantic proximity Read

Tocilizumab treatment leads to early resolution of lymphopenia and myeloid dysregulation in patients hospitalized with COVID-19Semantic proximity Read

Genetic inhibition of interleukin-6 receptor signaling and Covid-19Semantic proximity Read

Genetic Biomarkers as Predictors of Response to Tocilizumab in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.Semantic proximity Read

Investigation of genetic variations of IL6 and IL6R as potential prognostic and pharmacogenetics biomarkers: implications for COVID19 and neuroinflammatory disorders.Semantic proximity Read

A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patientsSemantic proximity Read

Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis.Semantic proximity Read

Investigation of Genetic Variations of IL6 and IL6R as Potential Prognostic and Pharmacogenetics Biomarkers: Implications for COVID-19 and Neuroinflammatory DisordersSemantic proximity Read

Heterogeneous associations between interleukin-6 receptor variants and phenotypes across ancestries and implications for therapy.Semantic proximity Read